Clinical Trials Logo

Erythematotelangiectatic Rosacea clinical trials

View clinical trials related to Erythematotelangiectatic Rosacea.

Filter by:

NCT ID: NCT06331533 Completed - Clinical trials for Erythematotelangiectatic Rosacea

Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea

Start date: November 1, 2022
Phase: Phase 4
Study type: Interventional

Investigation of the effectiveness of intradermal botulinum toxin A treatment in the treatment of erythematotelangiectatic rosacea (ETR) using clinical, biophysical, dermatoscopic and videocapillaroscopy.

NCT ID: NCT05360251 Recruiting - Clinical trials for Erythematotelangiectatic Rosacea

Pulsed Dye Laser and Intense Pulsed Light Configured With Different Wavelength Bands in Improving Erythematotelangiectatic Rosacea

Start date: March 27, 2022
Phase: N/A
Study type: Interventional

Pulsed dye laser(PDL) and intense pulsed light(IPL) has been widely used in improving rosacea. To compare the efficacy and safety of PDL and IPL configured with different wavelength bands(Delicate Pulsed Light, M22 590, M22 vascular filter) in the treatment of rosacea, we designed a prospective, randomized controlled trial. We hope to make a comparison between PDL and IPL,between broad-spectrum IPL and narrow-spectrum IPL, between single-band IPL and dual-band IPL, and also provide clinical basis for clinicians and patients to develop individualized treatment plans.

NCT ID: NCT04153188 Completed - Clinical trials for Erythematotelangiectatic Rosacea

Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea

Start date: January 15, 2019
Phase: Phase 4
Study type: Interventional

This study will compare treatment outcome with pulsed dye laser, when used used as an adjunctive treatment to oxymetazoline HCl 1% cream, compared to oxymetazoline HCL 1% cream alone, for patients with moderate or severe erythematotelangiectatic rosacea.

NCT ID: NCT03708263 Terminated - Clinical trials for Erythematotelangiectatic Rosacea

Evaluation of the New Laser PHOTOLASE PLV-585nm for the Treatment of Rosacea

ROSAPHOTOLASE
Start date: September 8, 2020
Phase: N/A
Study type: Interventional

Rosacea is a frequent dermatological condition, with a chronic and disturbing evolution that is characterized by redness, permanent erythema associated with telangiectasia (visible and permanent dilatation of the small vessels). It frequently affects men and women with fair skin and can have significant psycho-emotional consequences. To counteract the unaesthetic appearance of redness and eliminate telangiectasia, the use of the laser is proposed to the patient. This study is a single center prospective, randomized, controlled split face study to compare 532nm KTP laser versus 585 nm PLV Laser in terms of improvement of the symptoms in the treatment of Erythematotelangiectatic Rosacea 20 subjects will receive up to 3 laser treatments at day 0, month 2 and 4 and will be followed at month 6 and 12.

NCT ID: NCT02393937 Completed - Clinical trials for Papulopustular Rosacea

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

Start date: February 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of two Metronidazole Gels 1%, in the treatment of Rosacea.

NCT ID: NCT02268474 Completed - Clinical trials for Papulopustular Rosacea

Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea

Start date: September 2014
Phase: N/A
Study type: Interventional

A single center prospective, randomized, controlled split face study comparing a 532nm KTP laser with a 595nm PDL for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea. Subjects will receive laser treatments and will be followed at 6 weeks post-final laser treatment.

NCT ID: NCT02144181 Completed - Rosacea Clinical Trials

Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea

Start date: May 2014
Phase: N/A
Study type: Interventional

This is a prospective, multi-site (up to 5 sites), single-blinded, randomized trial. Up to 88 subjects will be enrolled and randomized to one of four treatment groups (4 Groups of 22 subjects), and will receive study treatments based on their assigned treatment group. Following study treatments, follow-up visits will occur at 90, 180 and 365 days from each subject's last study treatment.

NCT ID: NCT02052999 Completed - Clinical trials for Papulopustular Rosacea

Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients

Start date: February 2013
Phase: Phase 2
Study type: Interventional

The objective of this study is to determine the efficacy and safety of PAC-14028 1% cream of Amorepacific Corporation in patients with erythema-telangiectatic or papulopustular rosacea

NCT ID: NCT01756027 Completed - Clinical trials for Erythematotelangiectatic Rosacea

Feasibility Study: Ulthera System for the Treatment of Rosacea

Start date: November 2012
Phase: N/A
Study type: Interventional

Up to 12 subjects will be enrolled. Enrolled subjects will receive one or two Ultherapy treatments on the cheeks, depending on their assigned study group. Follow-up visits will occur 14, 30 and 90 days post-treatment. Study images will be obtained pre-treatment, 30-60 min post-treatment, and at each follow-up visit.

NCT ID: NCT01045551 Completed - Clinical trials for Papulopustular Rosacea

Open Label Pilot Study of Apremilast in Treatment of Rosacea

Start date: June 2010
Phase: Phase 2
Study type: Interventional

Rosacea is a chronic skin disorder with the signs and symptoms of facial flushing, persistent redness, small visible spider-like veins, papules (inflamed red bumps under the skin) and pustules. Rosacea is also a a recurring skin disorder. In addition to causing uncomfortable and embarrassing physical symptoms such as flushing, burning, and itching, rosacea can also contribute to lower self-esteem, which can have a significant psychosocial impact on quality of life. Rosacea flares can be triggered by every day factors such as sun exposure, heat, hot or caffeinated drinks, alcoholic beverages, spices and stress. Many of the currently available treatments for rosacea are only partially effective and some patients do not respond to them, or are unable to tolerate the side effects. This is a single-center, open label trial of Apremilast in ten (10) subjects with moderate to severe inflammatory rosacea who will be treated with Apremilast 20 mg twice per day for 12 weeks. Following the screening period and baseline visit, study subjects will return at weeks 1, 2, 4, 6, 8, 10 and 12. There is a follow up study visit at week 16. Recent research has shown an increase of specific proinflammatory cytokines in the biopsies of inflammatory lesions from rosacea and acne patients. The cytokines then trigger a chain of chemical responses in the body that likely result in the development of the papules an pustules that are seen in rosacea and acne patients. Apremilast is an oral agent that modulates multiple anti-inflammatory pathways and has pharmacodynamic properties with potential therapeutic benefit for treating inflammatory autoimmune disorders. The investigators therefore propose a pilot study to evaluate the potential for Apremilast to improve the signs and symptoms of moderate to severe inflammatory rosacea.